Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viemed HealthcareVMD +2.32%89 Return-on-Tangible-Equity is 13.19% as of Jun. 2026, which is 9% below its 10-year median of 14.57. GuruFocus rates VMD with a GF Score™ of 89/100 and a GF Value™ of $10.99 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Viemed Healthcare ranks better than 77.68% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Viemed Healthcare's annualized net income for the quarter that ended in Jun. 2026 was $11.1 Mil. Viemed Healthcare's average shareholder tangible equity for the quarter that ended in Jun. 2026 was $83.8 Mil. Therefore, Viemed Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 13.19%.
The historical rank and industry rank for Viemed Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
VMD'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.48 Med: 14.57 Max: 50.29
Current: 16.91
During the past 10 years, Viemed Healthcare's highest Return-on-Tangible-Equity was 50.29%. The lowest was 6.48%. And the median was 14.57%.
VMD's Return-on-Tangible-Equity is ranked better than 77.68% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.41
vs VMD: 16.91
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Viemed Healthcare Return-on-Tangible-Equity Related Terms
Viemed Healthcare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Viemed Healthcare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VMD vs OFIX, VREX, SI: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Viemed Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viemed Healthcare Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Viemed Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.19% mean?
Viemed Healthcare (VMD) has a Return-on-Tangible-Equity of 13.19% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viemed Healthcare and its competitors. This is near median its historical median of 14.57. Over the past decade, Viemed Healthcare's Return-on-Tangible-Equity has ranged from 6.48 to 50.29. According to the industry distribution chart, Viemed Healthcare ranks #169 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 22.3%.
Is Viemed Healthcare's Return-on-Tangible-Equity too high?
Viemed Healthcare's current Return-on-Tangible-Equity of 13.19% is near median its 10-year median of 14.57. Over the past 10 years, this metric has ranged from a low of 6.48 to a high of 50.29. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.41. Viemed Healthcare's value of 13.19% is 199.1% above this industry median. Based on the distribution chart, Viemed Healthcare ranks #169 out of 757 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Viemed Healthcare has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viemed Healthcare's Return-on-Tangible-Equity compare to OFIX and VREX?
According to the Medical Devices & Instruments industry distribution chart, Viemed Healthcare ranks #169 out of 757 companies for Return-on-Tangible-Equity. This places Viemed Healthcare in the top 22% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.41. Viemed Healthcare's value of 13.19% is 199.1% above this benchmark. Historically, Viemed Healthcare's own Return-on-Tangible-Equity has ranged from 6.48 to 50.29 over the past decade. While the company's 10-year median is 14.57 vs. the industry median of 4.41, Viemed Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.41, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viemed Healthcare's current Return-on-Tangible-Equity of 13.19% is 199.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viemed Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viemed Healthcare's current Return-on-Tangible-Equity is 13.19%, which is near median its own 10-year median of 14.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viemed Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Viemed Healthcare (VMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $10.99, compared to a current price of $9.04 — trading 17.7% below its estimated fair value. The current Return-on-Tangible-Equity is 13.19%, which is near median its 10-year median of 14.57 and 199.1% above the Medical Devices & Instruments industry median of 4.41. Viemed Healthcare's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Viemed Healthcare (VMD), the current Return-on-Tangible-Equity is 13.19% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viemed Healthcare (VMD) Overvalued in 2026?
Based on GuruFocus' analysis, Viemed Healthcare stock appears to be undervalued.
The current stock price of $9.04 is trading 17.7% below its estimated GF Value™ of $10.99.
GuruFocus considers Viemed Healthcare to be Modestly Undervalued.
Key valuation signals for VMD:
Return-on-Tangible-Equity: 13.19% (near median its 10-year median of 14.57)
GF Value™: $10.99 vs. price of $9.04 (17.7% below fair value)
Industry Position: 199.1% above the Medical Devices & Instruments median (#169 of 757)
No single metric tells the full story. See the VMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
89GF Score
Get the complete analysis for VMD
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMD has been successfully added to your 
